Hemopurifier® HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens

[Guest guest]

Hemopurifier® HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens

SAN DIEGO, July 7 /PRNewswire-FirstCall/ --

Aethlon Medical, Inc. the pioneer in developing therapeutic filtration devices to address infectious disease and cancer.

;

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.

;

However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

, ;As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

, ;Cancer: A treatment candidate to improve patient responsiveness, to established cancer therapies by removing immunosuppressive exosomes from circulation.

,Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.

,Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.

,Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

;

Continue Reading............

http://Hepatitis Cnewdrugs.blogspot.com/2010/07/hemopurifier-hcv-as-adjunct-therapy-to.html